CRIS — Curis, Inc.

Is CRIS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Curis, Inc. (CRIS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.80. The rating moved from Strong Oversold to Oversold on September 22, 2026.

See all oversold Healthcare stocks →

AI analysis

Curis is a pipeline-centric small‑cap biotech whose value is driven by clinical progress and capital access. Financial health is likely constrained by ongoing cash burn and limited commercial revenue, making near‑term dilution a material possibility. Sector developments that validate late‑stage rare‑disease biologics provide a constructive backdrop, but policy headwinds on drug pricing and a risk‑off market environment reduce financing and valuation support. Key near‑term catalysts would be positive clinical readouts, partnering or non‑dilutive financing; downside scenarios include trial setbacks, regulatory hurdles, or forced dilutive raises. Overall outlook is highly binary and dependent on upcoming program milestones and financing execution.

Key factors

  • Pipeline-driven company with valuation highly dependent on clinical readouts and asset milestones
  • Likely limited or negative commercial revenue and ongoing cash burn creating financing/dilution risk
  • Sector tailwinds for successful late‑stage rare-disease/biologics programs could lift sentiment for specialty pharma peers
  • Macroeconomic risk-off and reduced appetite for healthcare/device IPOs and financings limits near-term capital access
  • Policy pressure on drug pricing (Medicare negotiation) increases payer risk and potential downward pricing pressure
  • Typical small-cap biotech low liquidity and heightened share volatility

Risks

  • Negative or delayed clinical trial results that materially reduce program value
  • Insufficient cash runway requiring dilutive equity raises or unfavorable financing
  • Regulatory setbacks or prolonged review timelines
  • Downward pricing pressure and restricted market access from Medicare drug-price negotiation and payer actions
  • Competitive displacement from larger biopharma entrants or new combination therapies
  • Market sentiment swings and low liquidity causing outsized price moves independent of fundamentals

See today's live rating, score and targets

Members see the live hourly rating for CRIS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.